Davis, CA (PRWEB) March 18, 2014
Mytrus, a pioneer in electronic informed consent and leader in e-clinical technologies, announced today the appointment of a new Innovation Advisory Board comprised of leading industry experts who will help shape the future of clinical products and services offered by the Company.
“The members of our new Innovation Board have held key positions in the pharmaceutical industry throughout their careers and have a long tradition of innovating improvements in clinical research,” said Mytrus CEO Anthony Costello, who also will serve on the Innovation Advisory Board. “We are grateful for their willingness to work with us and we share a common commitment to improving the clinical trial experience for patients.”
Costello noted that more and more research shows better informed and more engaged patients lead to better research data and faster drug development timelines. “This group of experts has long recognized the importance of patient centricity in research and their input into our line of clinical trials technologies will be invaluable in helping us break new ground in trial improvement,” he said.
The Innovation Advisory Board members include:
Steven Cummings, MD - Co-founder of Mytrus and a leading expert in the design and implementation of clinical research studies. Dr. Cummings, the Chief Scientific Officer at Mytrus, also serves as Director of the San Francisco Coordinating Center, Emeritus Professor of Medicine, Epidemiology and Biostatistics at UCSF and Sr Scientist at CPMC Research Institute and Innovator-in-Residence at Roche-Genentech.
David G. Forster, J.D., M.A., C.I.P, Chief Compliance Officer, WIRB-Copernicus Group. Mr. Forster joined the Western Institutional Review Board (WIRB) in 1996 and currently serves as Chief Compliance Officer as well as a co-chair on a subcommittee of the Health and Human Services Secretary’s Advisory Committee on Human Research Protections (SACHRP)
Clay Johnston, MD, PhD - Dean of Medicine at the new University of Texas Dell Medical School in Austin. Dr. Johnston recently served as Director of the Clinical Translational Sciences Institute at the University of California, San Francisco, and is a leading expert in clinical trial methods.
Garry Neil, MD – Global Head of Research and Development at Medgenics. Dr. Neil is a leader in clinical trials innovation. At Johnson & Johnson, he served as Corporate Vice President of Science & Technology and Group President of Pharmaceutical Research and Development. Dr. Neil also is a Founder/Director and served as CEO of TransCelerate Biopharma, Inc., a respected, cross-industry initiative to improve the effectiveness and efficiency of industrial biopharmaceutical R&D.
Dr. John Orloff, MD - Global Head of Clinical Development at Merck Serono. Dr Orloff most recently served as Chief Medical Officer and Senior Vice President, Global Development for Novartis Pharma AG where he led the “Trials of the Future” initiative to bring innovation to the drug development process. He also served as Head of U.S. Medical and Drug Regulatory Affairs for North America.
Jane Perlmutter, PhD, MBA - Psychologist and leading patient advocate for clinical trial participants. Dr. Perlumutter also serves on the Clinical Trials Transformation Initiative (CTTI) initiative on Informed Consent.
Founded five years ago, Mytrus has become a leader in innovative e-clinical technologies with a focus on accessibility and usability for patients in clinical trials. The company’s flagship product for direct to patient (D2P) trials was first deployed by Pfizer in 2010 in the industry’s first clinical research study allowing patients to participate entirely from home. Since then, Mytrus has worked to develop a pioneering line of new patient-focused products for electronic informed consent, patient data collection and research results reporting on clinical trials.
Founded in 2009, Mytrus is a California-based clinical technology and services company which is revolutionizing traditional clinical trials with its simple, efficient, and patient-centered technologies. Creating interactive tools which improve patient comprehension and comfort, Mytrus streamlines the clinical trial process, dramatically improving patient recruitment timelines, increasing patient retention and reducing overall study costs for sponsors. At a time when bringing a drug to market can cost up to $1 billion, Mytrus provides solutions for pharmaceutical, biotech and device makers eager to find more cost effective ways to conduct research. Mytrus is partially owned by inVentiv Health, a global life science knowledge and services company innovating for the new health care environment.